Skip to main content
TipRanks
Go Ultimate75% OFF

Extendicare (0S9E) AI Stock Analysis

2 Followers
GB:0S9E

Extendicare

(LSE:0S9E)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Improving revenue and profitabilityThe company has established a multi-period improvement in revenue and operating profitability, providing evidence of strengthening execution rather than a single-quarter benefit. Continued earnings growth can support reinvestment, debt reduction, and service expansion across its care platform over the next several quarters.
Negative Factors
Higher leverage and balance-sheet sensitivityThe rise in debt relative to equity increases sensitivity to earnings volatility and financing conditions, even though recent liquidity and deleveraging have improved. Greater leverage can constrain capital allocation and reduce flexibility if operating performance weakens or investment requirements increase.

Extendicare (0S9E) vs. iShares MSCI United Kingdom ETF (EWC)

-20%0%20%40%60%80%100%GB:0S9E+49.88%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 2.77B
Dividend Yield
1.78%
Average Volume (3M)
164
Price to Earnings (P/E)
20.7
Beta (1Y)
-0.04
Revenue Growth
36.24%
EPS Growth
29.85%
Country
UK
Employees
23,500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Extendicare Business Overview & Revenue Model

Company Description

Extendicare Inc. operates across Canada, delivering a wide array of vital care and support services specifically designed for the senior population through its various subsidiaries. The company's diverse service portfolio includes long-term care faci...

Extendicare Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:4.74%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Extendicare reported substantial year-over-year growth in adjusted EBITDA, revenue, earnings, home health volumes, managed services, liquidity, and deleveraging, while its CBI acquisition and redevelopment program continued to advance. The main challenges were year-over-year Home Health margin pressure, expected moderation in market growth, uncertain Ontario rate timing, redevelopment delays, construction-cost and interest-rate uncertainty, and seasonal volatility. Management nevertheless characterized the company as financially flexible and maintained confidence in long-term demand and its growth opportunities.

Positive Updates

Strong Q3 Financial Performance
Adjusted EBITDA was $71.7 million, up 41% year-over-year and ahead of consensus. Net earnings of $0.354 per diluted share increased 26% from the prior-year period.

Negative Updates

Home Health Margin Pressure Year-over-Year
Home Health NOI margin declined 50 basis points from the prior year. Management attributed the reduction to technology and back-office investments made earlier in 2026 to support rapid growth and the absence of a 2026 rate increase in Ontario.

Company Guidance

Management expects underlying Home Health market growth to moderate over time to approximately 6% to 8% on an annualized basis, with funding increases substantially keeping pace with inflation and supporting NOI margins; it continues to expect annualized Managed Services margins of 50% to 55%. CBI finance and enterprise IT systems integration is expected to be completed by January 1, '27, with annualized synergies expected to total approximately $7.4 million by the time CBI is fully integrated in 2028, and synergies more reflective in '28 than in '27. Home Health is viewed as a 13% margin business with an opportunity to grow over time, 50 to another 100 basis points, over the next couple of years, not a 2027 thing. The company plans to open 4 new homes in 2027, bringing a further 832 beds online in the JV, with the next construction start targeted for spring 2027, and expects to review the dividend again early in the first quarter with year-end results.

Extendicare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0S9E against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:DRTSE:DR72OutperformCAD 276.56M8.6344.01%2.11%4.53%-55.43%
TSE:SIATSE:SIA70OutperformCAD 2.27B40.445.98%4.58%14.90%13.31%
TSE:CRRXTSE:CRRX63NeutralCAD 201.00M7.7923.35%2.58%3.42%40560.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%25%50%75%GB:0S9ETSE:CRRXTSE:SIATSE:DRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0S9E and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0S9EExtendicare Inc.29.199.7149.88%
TSE:CRRXCarerx Corporation3.18-0.13-3.96%
TSE:SIASienna Senior Living20.430.864.41%
TSE:DRMedical Facilities Corp17.103.0721.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.